Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective

Abstract

The conventional more-is-better dose selection paradigm is often inappropriate for novel molecularly targeted agents. In response, the US Food and Drug Administration (FDA) initiated Project Optimus to reform the dose optimization and dose selection paradigm in oncology drug development. Furthermore, the FDA recently also published draft guidance “Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases guidance for industry,” providing overviews on the rationale, importance, and principles of dose optimization from the regulatory perspective. However, detailed guidance on how to design dose optimization trials is still lacking; it is a key issue faced by drug developers. The article discusses statistical and design strategies of dose optimization in oncology by sharing current industry practice on dose-finding, delineating key statistical components for dose optimization trials, describing available design strategies, and providing recommendations and future directions. This article is a joint work of the Statistical Methods in Oncology Scientific Working Group (Dose-Optimization Workstream) of the American Statistical Association Biopharmaceutical Section.

KEYWORDS:

• Industry perspective
• Oncology
• Project optimus

Supplementary Materials

Appendix 1: List of software commonly used in the context of dose optimization.

Disclosure Statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.